GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Investments And Advances

Financiere de Tubize (LTS:0D53) Investments And Advances : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Financiere de Tubize Investments And Advances?

Financiere de Tubize's Investments And Advances for the quarter that ended in Dec. 2023 was €0.00 Mil.


Financiere de Tubize Investments And Advances Historical Data

The historical data trend for Financiere de Tubize's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Investments And Advances Chart

Financiere de Tubize Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Financiere de Tubize Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Financiere de Tubize Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Financiere de Tubize (LTS:0D53) Business Description

Traded in Other Exchanges
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (LTS:0D53) Headlines

No Headlines